Phathom Reports Q3 2026 Revenue of $84.7 Million, Reaffirms Guidance
Revenue rose 71% year over year and 14% from Q2. The company reported a $13.9 million net loss, positive operating cash flow for a second consecutive quarter, and more than 2 million VOQUEZNA prescriptions filled since launch through October 16, 2026.